Advanced search
Publication Cover
Clinical Lipidology Volume 4, 2009 - Issue 5
Submit an article Journal homepage
214
Views
0
CrossRef citations to date
0
Altmetric
Reviews

Visceral fat and cardiovascular risk in patients with polycystic ovary syndrome

Teresa CascellaCorrespondence[email protected]
,
Stefano Palomba
,
Francesco Giallauria
,
Ilario De Sio
,
Annamaria ColaoCorrespondence[email protected]
,
Gaetano LombardiCorrespondence[email protected]
,
Marcello Orio
&
Francesco Orio
 show all
Pages 623-632 | Published online: 18 Jan 2017

  • Azziz R, Woods KS, Reuna R et al.: The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89, 2745–2749 (2004).
  • Norman JR, Dewailly D, Legro SR et al.: Polycystic ovary syndrome. Lancet 370, 685–697 (2007).
  • Shaw LJ, Bairey Merz CN, Azziz R et al.: Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health – National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J. Clin. Endocrinol. Metab. 93, 1276–1284 (2008).
  • Solomon CG, Hu FB, Dunaif A et al.: Menstrual cycle irregularity and risk for Endocrinol. Metab. 87, 2013–2017 (2002).
  • Rexrode KM, Manson JE, Lee IM et al.: Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 108, 1688–1693 (2003).
  • Dahlgren E, Janson PO, Johansson S et al.: Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet. Gynecol. Scand. 71, 599–604 (1992).
  • Legro RS, Kunselman AR, Dodson WC et al.: Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84, 165–169 (1999).
  • Ehrmann DA, Barnes RB, Rosenfield RL et al.: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22, 141–146 (1999).
  • Sam S, Dunaif A: Polycystic ovary syndrome: syndrome XX? Trends Endocrinol. Metab. 14, 365–370 (2003).
  • Talbott E, Guzick D, Clerici A et al.: Coronary artery disease risk factors in women with polycystic ovary syndrome. Arterioscler. Thromb. Vasc. Biol. 15, 821–826 (1995).
  • Ford ES: The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II mortality study. Atherosclerosis 173, 309–314 (2004).
  • Ritchie SA, Connell JMC: The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis. 17, 319–326 (2007).
  • Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C: Cardiovascular risk in women with polycystic ovary syndrome. J. Cardiovasc. Med. (Hagerstown) 9(10), 987–992 (2008).
  • Cussons AJ, Watts GF, Burke V et al.: Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum. Reprod. 23, 2352–2358 (2008).
  • Goverde AJ, van Koert AJ, Eijkemans MJ et al.: Indicators of metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum. Reprod. 24, 710–717 (2009).
  • Cascella T, Palomba S, DeSio I et al.: Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum. Reprod. 23, 153–159 (2008).
  • Visceral fat (VF) amount is associated with subclinical cardiovascular disease in polycystic ovary syndrome (PCOS) patients.
  • Yildrim B, Sabir N, Kaleli B: Relation of intra-abdominal fat distribution to metabolic disorders in non obese patients with polycystic ovary syndrome. Fertil. Steril. 79, 1358–1364 (2003).
  • Zwirska-Korczala K, Sodowski K, Konturek SJ et al.: Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome. J. Physiol. Pharmacol. 59, 161–178 (2008).
  • Grundy SM, Cleeman JI, Daniels SR et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute scientific statement. Circulation 112, 2735–2752 (2005).
  • Bigaard J, Frederiksen K, Tjonneland A et al.: Waist circumference and body composition in relation to all-cause mortality in middle-aged women. Int. J. Obes. 29, 778–784 (2005).
  • Palmieri J: Implementing the National Cholesterol Education Program’s update to the ATP III report. Manag. Care Interface 18, 44–49 (2005).
  • Cussons AJ, Stuckey BG, Wayys GF: Cardiovascular disease in the polycystic ovary syndrome: new insights and prospectives. Atherosclerosis 185, 227–239 (2006).
  • Legro RS, Kunselman AR, Dunaif A: Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am. J. Med. 111, 607–613 (2001).
  • Macut D, Panidis D, Glisic B et al.: Lipid and lipoprotein profile in women with polycystic ovary syndrome. Can. J. Physiol. Pharmacol. 86, 199–204 (2008).
  • Dejager S, Pichard C, Giral P et al.: Smaller LDL particle size in women with polycystic ovary syndrome compared with controls. Clin. Endocrinol. (Oxf.) 54, 455–462 (2001).
  • Yilmaz M, Biri A, Bukan N et al.: Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol. Endocrinol. 20, 258–263 (2005).
  • Glueck CJ, Papanna R, Wang P et al.: Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52, 908–915 (2003).
  • Warnick GR, Nauck M, Rifai N: Evolution of methods for measurement of HDLcholesterol. From ultracentrifugation to homogenous assays. Clin. Chem. 47, 1579–1596 (2001).
  • Conway GS, Agrawal R, Betteridge DJ et al.: Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 37, 119–125 (1992).
  • Dullaart RP, Sluiter WJ, Dikkeschei LD et al.: Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur. J. Clin. Invest. 24, 188–194 (1994).
  • Talbott E, Clerici A, Berga SL et al.: Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case–control study. J. Clin. Epidemiol. 51, 415–422 (1998).
  • Reaven GM, Chen YD, Jeppesen J et al.: Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J. Clin. Invest. 92, 141–146 (1993).
  • Demerath EW, Reed D, Rogers N et al.: Visceral adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels. Am. J. Clin. Nutr. 88, 1263–1271 (2008).
  • Natural Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults treatment panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 106, 3143–3421 (2002).
  • Austin MA, Breslow JL, Hennekens CH et al.: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260, 1917–1921 (1988).
  • Berneis K, Rizzo M, Lazzarini V et al.: Atherogenic lipoprotein phenotype and low density lipoproteins size and subclasses in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 186–189 (2007).
  • Macut D, Damjanovic S, Panidis D et al.: Oxidized low-density lipoprotein (OxLDL) concentration – early marker of an altered lipid metabolism in young women with PCOS. Eur. J. Endocrinol. 155, 131–136 (2006).
  • Stamets K, Taylor DS, Kunselman A et al.: A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil. Steril. 81, 630–637 (2004).
  • Vigorito C, Giallauria F, Palomba S et al.: Beneficial effects of a structured exercise training program on cardiopulmonary function capacity in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 1379–1384 (2007).
  • Sathyapalan T, Kilpatrick ES, Coady AM et al.: The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J. Clin. Endocrinol. Metab. 94, 103–108 (2009).
  • Banaszewska B, Pawelczyk L, Spaczynski RZ et al.: Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J. Clin. Endocrinol. Metab. 92, 456–461 (2007).
  • Legro RS, Azziz R, Ehrmann D et al.: Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J. Clin. Endocrinol. Metab. 88, 5137–5144 (2003).
  • Palomba S, Falbo A, Zullo F et al.: Evidencebased and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev. 30, 1–50 (2009).
  • Extensively shows the potential effects and use of metformin in PCOS women.
  • Fleming R, Hopkinson ZE, Wallace AM et al.: Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J. Clin. Endocrinol. Metab. 87, 569–574 (2002).
  • Moghetti P, Castello R, Negri C et al.: Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab. 85, 139–146 (2000).
  • Diamanti-Kandarakis E, Mitrakou A, Raptis S et al.: The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83, 2699–2705 (1998).
  • Gambineri A, Pelusi C, Genghini S et al.: Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 60, 241–249 (2004).
  • Creatsas G, Koliopoulos C, Mastorakos G: Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann. NY Acad. Sci. 900, 245–252 (2000).
  • Carmina E, Legro RS, Stamets K et al.: Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum. Reprod. 11, 2289–2293 (2003).
  • Ehrmann DA: Polycystic ovary syndrome. N. Engl. J. Med. 352, 1223–1236 (2005).
  • Yildiz BO, Knochenhauer ES, Azziz R: Impact of obesity on the risk for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 931, 162–168 (2008).
  • Escobar-Morreale HF, San Millán JL: Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol. Metab. 18, 266–272 (2007).
  • Shi Y, Guo M, Yan J et al.: Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome. Neuroendocrinol. Lett. 28, 807–810 (2007).
  • Ogden CL, Yanovski SZ, Carroll MD et al.: The epidemiology of obesity. Gastroenterology 132, 2087–2102 (2007).
  • Liou TH, Yang JH, Hsieh CH et al.: Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertil. Steril. DOI: 10.1016/j.fertnstert.2008.09.003 (2008) (Epub ahead of print).
  • Orio F Jr, Palomba S, Spinelli L et al.: The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case–control study. J. Clin. Endocrinol. Metab. 89, 3696–3701 (2004).
  • Magnotti M, Futterweit W: Obesity and the polycystic ovary syndrome. Med. Clin. N. Am. 91, 1151–1168 (2007).
  • Dunaif A: Insulin resistance and polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18, 774–800 (1997).
  • Gambineri A, Pelusi C, Manicardi E et al.: Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 53, 2353–2358 (2004).
  • Gambineri A, Pelusi C, Vicennati V et al.: Obesity and the polycystic ovary syndrome. Int. J. Obes. Relat. Metab. Disord. 26, 883–896 (2002).
  • Moran LJ, Pasquali R, Teede HJ et al.: Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil. Steril. DOI: 10.1016/j.fertnstert.2008.09.018 (2008) (Epub ahead of print).
  • Orio F, Giallauria F, Palomba S et al.: Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women. Clin. Endocrinol. (Oxf.) 68, 976–981 (2008).
  • Palomba S, Giallauria F, Falbo A et al.: Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum. Reprod. 23, 642–650 (2008).
  • Yassine HN, Marchetti CM, Krishnan RK et al.: Effects of exercise and caloric restriction on insulin resistance and cardiometabolic risk factors in older obese adults – a randomized clinical trial. J. Gerontol. A Biol. Sci. Med. Sci. 64, 90–95 (2009).
  • Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548–2556 (2004).
  • Packard RR, Libby P: Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem. 54, 24–38 (2008).
  • Puder JJ, Varga S, Kraenzlin M et al.: Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J. Clin. Endocrinol. Metab. 90, 6014–6021 (2005).
  • Orio F Jr, Palomba S, Cascella T et al.: Adiponectin levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88, 2619–2623 (2003).
  • Carmina E, Orio F, Palomba S et al.: Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am. J. Med. 119, 356.e1–356.e6 (2006).
  • Lee NK, Sowa H, Hinoi E et al.: Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456–469 (2007).
  • Aroda V, Ciaraldi TP, Chang SA et al.: Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil. Steril. 89, 1200–1208 (2008).
  • Ohashi N, Ito C, Fujikawa R, Yamamoto H: The impact of visceral adipose tissue and high-molecular weight adiponectin on cardio-ankle vascular index in asymptomatic Japanese subjects. Metabolism 58, 1023–1029 (2009).
  • Ohman MK, Wright AP, Wickenheiser KJ et al.: Visceral adipose tissue and atherosclerosis. Curr. Vasc. Pharmacol. 7, 169–179 (2009).
  • Janssen I, Katzmarzyk PT, Ross R et al.: Fitness alters the associations of BMI and waist circumference with total and abdominal fat. Obes. Res. 12, 525–537 (2004).
  • Jung C, Fischer N, Fritzenwanger M et al.: Association of waist circumference, traditional cardiovascular risk factors, and stromal-derived factor-1 in adolescents. Pediatr. Diabetes 10(5), 329–335 (2009)
  • Dagenais GR, Yi Q, Mann JF et al.: Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am. Heart J. 149, 54–60 (2005).
  • Gasteyger C, Tremblay A: Metabolic impact of body fat distribution. J. Endocrinol. Invest. 25, 876–883 (2002).
  • DeNino WF, Tchernof A, Dionne IJ et al.: Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care. 24, 925–932 (2001).
  • Diamanti-Kandarakis E: Role of obesity and adiposity in polycystic ovary syndrome. Int. J. Obes. 31(Suppl. 2), S8–S13 (2007).
  • Després JP, Lemieux I, Bergeron J et al.: Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler. Thromb. Vasc. Biol. 28, 1039–1049 (2008).
  • Lord J, Thomas R, Fox B et al.: The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 113, 1203–1209 (2006).
  • VF is the most significant variable correlating with metabolic dysfunction in women with PCOS. These data support the hypothesis that VF causes insulin resistance.
  • Carmina E, Bucchieri S, Esposito A et al.: Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J. Clin. Endocrinol. Metab. 92, 2500–2505 (2007).
  • Barber TM, Golding SJ, Alvey C et al.: Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93, 999–1004 (2008).
  • Demonstrates that PCOS cases and BMI/fat mass-matched control women are indistinguishable with respect to distribution of fat within visceral, abdominal subcutaneous depots, despite significant differences in insulin resistance between these two groups.
  • Lewy VD, Danadian K, Witchel SF, Arslanian S: Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J. Pediatr. 138, 38–44 (2001).
  • Ibáñez L, de Zegher F: Ethinylestradioldrospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J. Clin. Endocrinol. Metab. 89, 1592–1597 (2004).
  • Ibáñez L, López-Bermejo A, Díaz M et al.: Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche J. Clin. Endocrinol. Metab. 93, 1841–1845 (2008).
  • Demonstrates that long-term metformin treatment reduces total and VF in low birth-weight precocious pubarche girls, and delays menarche without attenuating linear growth.
  • Kelly CC, Lyall H, Petrie JR et al.: Low grade chronic inflammation in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 86, 2453–2455 (2001).
  • Orio F Jr, Palomba S, Cascella T et al.: The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 2–5 (2005).
  • Tarkun I, Cetinarslan B, Türemen E et al.: Asssociation between circulating tumor necrosis factor-a, interleukin-6, and insulin resistance in normal-weight women with polycystic ovary syndrome. Metab. Syndr. Relat. Disord. 4, 122–128 (2006).
  • Carmina E, Bucchieri S, Mansueto P et al.: Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertil. Steril. 91, 1332–1335 (2009).
  • Atiomo WU, Fox R, Condon JE et al.: Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin. Endocrinol. (Oxf.) 52, 487–492 (2000).
  • Nácul AP, Andrade CD, Schwarz P et al.: Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity. Eur. J. Obstet. Gynecol. Reprod. Biol. 133, 191–196 (2007).
  • Orio F Jr, Palomba S, Cascella T et al.: Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 89, 4588–4593 (2004).
  • Yarali H, Yildirir A, Aybar F et al.: Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil. Steril. 76, 511–516 (2001).
  • Kelly CJ, Speirs A, Gould GW et al.: Altered vascular function in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87, 742–746 (2002).
  • Paradisi G, Steinberg HO, Hempfling A et al.: Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103, 1410–1415 (2001).
  • Talbott EO, Zborowski JV, Rager JR et al.: Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 89, 5454–5461 (2004).
  • Rajendran S, Willoughby SR, Chan WP et al.: Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 204, 509–514 (2009).
  • Tasali E, Van Cauter E, Hoffman L, Ehrmann DA: Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93, 3878–3884 (2008).
  • Sturm W, Sandhofer A, Engl J et al.: Influence of visceral obesity and liver fat on vascular structure and function in obese subjects. Obesity (Silver Spring) DOI: 10.1038/oby.2009.81 (2009) (Epub ahead of print).
  • Lu Q, Cheng LT, Wang T et al.: Visceral fat, arterial stiffness, and endothelial function in peritoneal dialysis patients. J. Ren. Nutr. 18, 495–502 (2008).
  • Levy D, Garrison RH, Savage DD et al.: Prognostic implication of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322, 1561–1566 (1991).
  • Vetta F, Cicconetti P, Ronzoni S et al.: Hyperinsulinaemia, regional adipose tissue distribution and left ventricular mass in normotensive, elderly, obese subjects. Eur. Heart J. 19, 326–331 (1998).
  • Tíras MB, Yalcìn R, Noyan V et al.: Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Hum. Reprod. 14, 1949–1952 (1999).
  • Vgontzas AN, Bixler EO, Chrousos GP: Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J. Intern. Med. 254, 32–44 (2003).
  • Orio F Jr, Giallauria F, Palomba S et al.: Cardiopulmonary impairment in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91, 2967–2971 (2006).
  • Orio F Jr, Palomba S, Giallauria F, Colao A, Vigorito C: Impaired cardiopulmonary parameters in young women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 66(1), 152–153 (2007).
  • Giallauria F, Palomba S, Cascella T et al.: Abnormal heart rate recovery after maximal cardiopulmonary exercise stress testing in young women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 68(1), 88–93 (2008).
  • Giallauria F, Palomba S, De Sio I et al.: Inflammatory markers and visceral fat are inversely associated with maximal oxygen consumption in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 70(3), 394–400 (2009).
  • Demonstrates that VF, C reactive protein, and white blood cell count were independently and inversely associated with VO2 max, a measure of cardiorespiratory fitness, in women with PCOS, even after adjustment for physical activity level.
  • Giallauria F, Orio F, Lombardi G et al.: Relationship between heart rate recovery and inflammatory markers in patients with polycystic ovary syndrome: a cross-sectional study. J. Ovarian Res. 2(1), 3–9 (2009).
  • Pierpoint T, McKeigue PM, Isaacs AJ et al.: Mortality of women with polycystic ovary syndrome at long-term follow-up. J. Clin. Epidemiol. 51, 581–586 (1998).
  • Wild S, Pierpoint T, McKeigue P et al.: Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin. Endocrinol. (Oxf.) 52, 595–600 (2000).
  • Diamanti-Kandarakis E, Paterakis T, Alexandraki K et al.: Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum. Reprod. 21, 1426–1431 (2006).
  • Orio F, Manguso F, Di Biase S et al.: Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. Eur. J. Endocrinol. 157, 69–73 (2007).
  • Orio F Jr, Palomba S, Cascella T et al.: Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J. Clin. Endocrinol. Metab. 90, 6072–6076 (2005).
  • Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI et al.: Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 2453–2461 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.